현재 위치
Home
제약산업 입장에서 본 우리나라 의약품 등재제도의 문제점
Industry perspective on current HTA system in Korea
-
- 발행기관
- 한국보건사회약료경영학회 바로가기
-
- 간행물
- 한국보건사회약료경영학회지 바로가기
-
- 통권
- Volume4 Number1 (2015.11)바로가기
-
- 페이지
- pp.14-22
-
- 저자
-
- 언어
- 한국어(KOR)
-
- URL
- https://www.earticle.net/Article/A326921
※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.
원문정보
초록
- 영어
- Positive list system was introduced in 2007 as a part of DERP (Drug Expenditure Rationalization Plan) in Korea. The purpose of this system is allocation efficiency based on value for money. Value is evaluated by HTA (Health Technology Assessment) focusing on clinical usefulness and cost-effectiveness with proven evidence at the time of launch. This article is prepared to assess current HTA system from industry perspective considering value-based decision making. It seems that current HTA process has several areas to improve since reimbursement decision is too much dependent on launch time evidence which may not reflect true value. The difficulty of showing superior efficacy does not necessarily mean there isn’t any additional value for society. New treatment option brings value of better treatment mixture. Drugs with unquantifiable benefit also have their own value. The issue is that current HTA often fails to capture these values. Current HTA focusing on statistical significance sometimes fails to find clinically significant value. One of big issues is that uncertain evidence of effect is often interpreted as the evidence of no value. ICER dependent decision making may result in unreasonable decision such as non-reimbursement of highly valuable drug for society. HTA methodology needs to be evolved in accordance with advancement of science. The flexible pricing method such as risk-sharing and holistic approach like MCDA (multiple criteria decision analysis) in decision-making is required for better patient access. This decision should incorporate fair assessment for innovativeness, clinical usefulness and equity not only for cost-effectiveness or budget impact.
목차
Abstract
본론
선별등재제도 평가: 효율성, 형평성, 접근성, 지속 가능성
가치와 근거 그리고 의사결정
가치(Value)
근거(Evidence)
의사결정(Decision making)
결론
감사의 말씀
참고문헌
키워드
pricing and reimbursement HTA value-based decision-making저자
간행물 정보
발행기관
-
- 발행기관명
- 한국보건사회약료경영학회 [Korean Academy of Social & Managed Care Phemacy]
- 설립연도
- 2009
- 분야
- 의약학>약학
- 소개
- 본 학회는 비영리 학술단체로서 환자의 삶의 질 향상을 위한 약료(pharmaceutical care)가 보장될 수 있도록 약료경영약학(managed care pharmacy)을 발전시키는 데 궁극 목적을 두고 다음과 같은 활동을 전개하여 사회에 기여하며 회원 상호간의 친목을 도모한다.
간행물
-
- 간행물명
- 한국보건사회약료경영학회지 [Journal of Korean Academy of Managed Care Pharmacy]
- 간기
- 반년간
- pISSN
- 2092-8394
- 수록기간
- 2009~2022
- 십진분류
- KDC 518 DDC 615
이 권호 내 다른 논문 / 한국보건사회약료경영학회지 Volume4 Number1
피인용수 : 0건 (자료제공 : 네이버학술정보)
함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.
출처 : 네이버학술정보
0개의 논문이 장바구니에 담겼습니다.